Industry
With the achievement of this new milestone, both companies will now advance this research which focuses on developing innovative therapies for metabolic diseases.
The new group will have annual revenues of approximately 3.5 billion euros ($3.7 billion), the companies said.
FB-001 is a rationally designed consortium of 148 defined bacterial strains with unprecedented diversity, representing a complete microbiome replacement
Benjamin Hadida discusses how to validate innovative clinical trial design and overcome challenges of robust-large scale manufacturing.
Rebyota Approved for the Prevention of Recurrence of Clostridioides difficile Infection in Adults
The discovery contributes to the understanding of the infant gut microbiome and how it evolves during development.
This strategic partnership is set to accelerate the international distribution of Microba’s microbiome testing into primary and specialist healthcare, and move our testing deeper into routine patient management.
Yvonne Nyavor discusses the improvement of analysis methods for Live Biotherapeutics Products.
Important goal reached by the Novara-based pharmaceuticals company, specialised in the production and marketing of live biotherapeutic products.
Formal approval of BiomeBank’s first-generation donor derived microbiome-based therapy product, BIOMICTRA registered in the Australian Register of Therapeutic Goods
